3 reasons CSL stock is a great long-term investment

CSL has been a high-performing stock. Is it a buy today? UBS has the answer.

| More on:
Doctor doing a telemedicine using laptop at a medical clinic

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) stock has been a strong performer over the long term with a rise of more than 300% over the past decade. Is the ASX healthcare share a good buy today?

The company is the largest biotech company in Australia, but the question is whether it can continue growing profit at a decent pace to push CSL stock higher. There are three factors I'll look at to decide if CSL stock is appealing.

Investing for growth

The business continues to put a lot of money into investing for the future.

For example, the new RIKA blood plasma donation system is meant to deliver a number of benefits. This system completes one collection in less than 35 minutes, on average, which reduces the donation time by around 30%. There is a rollout plan for the next 18 months for CSL's centres. The individualised Nomogram will reportedly improve the average donation yield by around 10%. There should also be a reduction in biohazard disposable waste by between 10% to 15%. The system will also help improve productivity and help boost the gross profit margin.

CSL continues to invest hundreds of millions of dollars in research and development across its various segments. That spending can unlock the newest healthcare treatments or vaccines, creating a new earnings stream, and helping CSL stock. In the FY24 half-year result, CSL said its R&D spending increased from US$593 million last year to US$669 million this year.

New Tullamarine site

CSL recently gave investors a site tour presentation, which included references to the new Tullamarine property, a state-of-the-art flu vaccine production facility.

The broker UBS said the Tullamarine building is under construction for CSL Seqirus, which will produce flu vaccines in cell culture. The new site is being built using a variety of techniques and facility configurations that will allow for "best in class" operational facility.

CSL will benefit from digital monitoring and release of batches, which UBS reported was described as "substantially labour saving".

Another benefit of this Tullamarine site will be better clean room security by placing machinery parts that need cleaning outside the clean environment.

The third benefit suggested by UBS was the ability to scale production at this facility as needed.

Good earnings growth expected

Estimates by UBS suggest the business is expected to see excellent earnings per share (EPS) growth over the next few years.

In FY24, owners of CSL stock are currently expected to see EPS of US$6.29 in FY24, US$7.45 in FY25, US$8.91 in FY26, US$10.69 in FY27 and US$11.86 in FY28.

If those estimates were to become reality, it would mean the CSL profit could grow by around 90% between FY24 and FY28. If that occurs, it would be very supportive for CSL stock in my opinion. Profit growth is one of the reasons why UBS has a buy rating on CSL stock with a price target of $330.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

two doctors smile as they sit together at a desk looking at a patient's Xray.
Healthcare Shares

This ASX 200 healthcare stock just hit an all-time high: Is it too late to buy?

The valuation of this high-performer has soared.

Read more »

A smiling woman sits in a cafe reading a story on her phone about Rio Tinto and drinking a coffee with a laptop open in front of her.
Healthcare Shares

1 magnificent ASX stock down 10% to buy and hold forever

Analysts say this high-quality stock is a great option for investors right now.

Read more »

ventilator mask
Healthcare Shares

3 reasons ResMed shares 'are just too cheap!'

This stock could still produce healthy gains, according to one fund manager.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

2 ASX healthcare shares rocking higher on big news

This 'spray-on skin' company and cancer-fighting biotech have exciting news for shareholders today.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Insider still buying Mesoblast shares despite 230% rise this year: Should you buy?

This high-flying share is still reporting insider buying. Should you buy too?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Buy CSL shares for growing dividends and 'compelling long-term tailwinds'

CSL has increased both its interim and final dividend every year since 2021.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Resmed share price higher despite CEO hitting sell on 14,683 shares

ResMed's CEO just sold $4.8 million worth of his own company's shares.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Why this high-flying ASX 200 healthcare stock just crashed 11%

Neuren Pharmaceuticals just dropped its 1Q FY24 report on DAYBUE sales.

Read more »